Tsukuda M, Tamamushi N, Mochimatsu I, Mitarai K, Kaneko M, Sawaki S
Gan To Kagaku Ryoho. 1986 Jan;13(1):53-9.
The prognosis of nasopharyngeal carcinoma (NPC) is very poor, due to the extreme failure of the immuno-surveillance mechanism in such cases. As an immunotherapeutic agent, OK-432 was administered to NPC patients. Cases were divided into two groups. One was given OK-432 for less than 6 months (short-term group), while a long-term group, was treated with OK-432 for over 6 months. These two groups were evaluated for immunological activity and prognosis. As immunological parameters, the numbers of white blood cells and lymphocytes were counted, and delayed skin reactivities with Su-PS and PPD were determined. No influence on the number of white blood cells and lymphocytes could be observed in either of the two groups. However, the skin tests showed better improvement of immunity in the long-term group than in the short-term cases. Furthermore, these reactivities correlated well with the clinical status of NPC patients. As to the absolute number of lymphocytes, improvement in the long-term NPC group was delayed in comparison to that of another head and neck carcinoma group given long-term OK-432 treatment. The prognosis of the long-term administered group was apparently better than that of the short-term group. Long-term administration of OK-432 is therefore indispensable for the treatment of NPC cases, because of the extreme decline of their immunity.
由于鼻咽癌（NPC）患者免疫监视机制严重失灵，其预后非常差。作为一种免疫治疗药物，OK-432被应用于鼻咽癌患者。病例被分为两组。一组接受OK-432治疗少于6个月（短期组），而长期组接受OK-432治疗超过6个月。对这两组患者的免疫活性和预后进行评估。作为免疫参数，计数白细胞和淋巴细胞数量，并测定对Su-PS和PPD的迟发型皮肤反应性。两组中均未观察到对白细胞和淋巴细胞数量有影响。然而，皮肤试验显示长期组的免疫改善情况优于短期组。此外，这些反应性与鼻咽癌患者的临床状况密切相关。关于淋巴细胞的绝对数量，长期鼻咽癌组的改善相较于另一接受长期OK-432治疗的头颈癌组有所延迟。长期给药组的预后明显优于短期组。因此，由于鼻咽癌患者免疫力极度下降，长期给予OK-432对于鼻咽癌病例的治疗不可或缺。
